Toripalimab
Total Neoadjuvant Treatment
Ruijin Hospitalmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Total Neoadjuvant Treatment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin West China Hospital | Phase 3 | B |
ETOPOSIDE West China Hospital | Phase 3 | B |
CIS-DIAMMINEDICHLOROPLATINUM II West China Hospital | Phase 3 | B |
Capecitabine Seoul National University Hospital | Phase 2/3 | B |
FLUOROURACILUM Seoul National University Hospital | N/A | D |
Same molecule, other indications
Toripalimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →